Group 1 - The core point of the article is that Shize Biopharmaceutical (Suzhou) Co., Ltd. has recently completed a C-round financing of 400 million RMB, marking its continuous market financing for five consecutive years [1] - Shize Biopharmaceutical was established in 2021 and is located in Suzhou, focusing on research and experimental development [1] - The company has a registered capital of 13.148 million RMB and has completed its C-round financing by 2026, with a transaction amount of 400 million RMB [1] Group 2 - Shize Biopharmaceutical has made investments in five external companies and holds 62 trademark registrations and 24 patents [1] - The company has three administrative licenses [1] - The shareholders of Shize Biopharmaceutical include Li Xiang, Suzhou Lirun Equity Investment Center, Beijing Qiming Rongxin Equity Investment Partnership, Suzhou Shize Dingao Biotechnology Partnership, and Shanghai Shize Yi Technology Partnership [1]
士泽生物医药（苏州）有限公司获“C轮”融资，金额4亿人民币
Sou Hu Cai Jing·2026-01-14 05:26